This material was developed by Sanofi Genzyme as part of the risk minimization plan for KEVZARA™.
It is not intended for promotional use.

KEVZARA (sarilumab) Appropriate Use Letter

INDICATION

KEVZARA (sarilumab) is indicated in the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Dear Healthcare Professional:

Please take careful note of this important safety information regarding KEVZARA (sarilumab). This information is being provided to assist you in the optimal use of KEVZARA for the treatment of adult patients with rheumatoid arthritis and facilitate the discussion with your patient pertaining to the specific important risks listed below:

- Serious infections
- Laboratory abnormalities (absolute neutrophil count (ANC), platelet count, transaminases levels, lipid parameters)
- Gastrointestinal perforations

The accompanying KEVZARA HCP Education/Discussion Guide includes more detailed information and addresses how to manage and minimize these risks.

You should discuss the risks associated with KEVZARA therapy with patients or their caregivers. Additionally, please provide the patient or caregiver with the Patient Card, included in the starter kit. This card serves as a reminder for the patient to advise other HCPs involved with their medical care that they are receiving KEVZARA. This is especially important in case of medical emergencies and/or if new HCPs become involved with their care.

REPORTING ADVERSE EVENTS

Please report to Sanofi Genzyme any medication errors and/or adverse events suspected to be associated with the use of KEVZARA by telephone at 1-800-589-6215 or by email at canada.pharmacovigilance@sanofi.com.

Refer to the full Product Monograph (PM) for extended prescribing recommendations. The KEVZARA PM can be found at sanofigenzyme.ca or by contacting Sanofi Genzyme. For additional medical information, please call Sanofi Genzyme at 1-800-589-6215. This information is also posted on the Sanofi Genzyme website.

HCPs should advise their patients to read in full the accompanying Patient Package Insert (PPI) and Instructions for Use (IFU) leaflet. HCPs are also encouraged to remind their patients to contact their HCP if they experience any of the signs and symptoms discussed in the PPI.